Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...

2024-11-20 07:20 1110

Datasea Pre-Announces Full-Year Fiscal 2025 Revenue of $90 Million, Representing a Year-Over-Year Increase of 275%, with Expected Significant Gross Profit Improvement

BEIJING, Nov. 19, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-registered digital technology company focused on innovations in acoustic high-tech and 5G AI multimodal digital technologies, today pre-announced that its revenue for the fiscal year ending Jun...

2024-11-19 22:45 1523

Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays

FREMONT, Calif., Nov. 19, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker disco...

2024-11-19 22:12 1045

Say Hello to 3.0: Datarithm Releases Latest Version of Inventory Management Solution

SYRACUSE, N.Y., Nov. 19, 2024 /PRNewswire/ -- In a landscape marked by intense competition, rising costs, and stringent regulatory requirements, independent pharmacies face an array of challenges that threaten their viability and success. Today, Datarithm® is proud to announce a solution to these...

2024-11-19 22:00 899

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...

2024-11-19 21:26 979

Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity

* "DigiCoach program" is a pilot program by Singapore Health Promotion Board, Health2Sync, and Abbott that aims to help individuals with pre-diabetes or high BMI prevent or delay the onset of diabetes. * Participants can use a continuous glucose monitoring (CGM) device and the Health2Sync mob...

2024-11-19 21:00 1028

2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries

AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging thei...

2024-11-19 21:00 338

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...

2024-11-19 20:30 805

Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...

2024-11-19 19:30 1513

Digital Medicine Society Launches Resources to Navigate Global Digital Health Regulatory Pathways

Resources will speed the expansion of digital health products worldwide, improving global patient access BOSTON, Nov. 19, 2024 /PRNewswire/ -- Today, the Digital Medicine Society (DiMe) unveiled a suite of resources to guide industry in evaluating international regulatory pathways. These resourc...

2024-11-19 19:00 933

SiPH Collaborates with IBM to Enhance Pathology Information System with Computational Advances and AI to Support Patients in Thailand and ASEAN

BANGKOK, Nov. 19, 2024 /PRNewswire/ -- Siriraj Piyamaharajkarun Hospital (SiPH), operating under Faculty of Medicine Siriraj Hospital, today announced a successful transformation of its Pathology Information System (PIS) using advanced computational technologies and artificial intelligence. In c...

2024-11-19 17:07 1338

SiPH Collaborates with IBM to Enhance Pathology Information System with Computational Advances and AI to Support Patients in Thailand and ASEAN

RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development

BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors. Polo-like kinase 1 (PLK1) is a h...

2024-11-19 16:00 873

RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development

TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects

TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July 2023, the U.S. Food & Drug Administration (FDA) accepted T...

2024-11-19 14:08 967

GHIT Fund Awarded Open Philanthropy Grant to Expand Funding Sources for Global Health R&D

TOKYO, Nov. 19, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is pleased to announce that Open Philanthropy, a grantmaking organization based inSan Francisco, California, has awarded funding for efforts to cultivate new partnerships and secure resources from the private...

2024-11-19 09:00 1088

SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...

2024-11-19 08:00 1503

Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has received full appro...

2024-11-19 07:40 1397

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nucl...

2024-11-19 06:24 1408

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024

* 78-Week results from Phase III randomized controlled trial (RCT) including switching data from reference denosumab to CT-P41 (biosimilar candidate of denosumab) demonstrate comparable efficacy and safety results; Results support the therapeutic equivalence of CT-P41 and reference denosumab in...

2024-11-19 02:15 1255

WAT Medical Continues Support for Red Cross and Veterans Association

VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly reaffirms its commitment to community support by donating to the American Red Cross and the American Veterans Association. These donations are part of the company's pledge to contribute a portion of the proceeds from...

2024-11-18 22:30 836

WAT Medical Continues Support for Red Cross and Veterans Association

C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...

2024-11-18 22:00 1348

C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

123 4 5 ... 610

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 283 media titles]

2024-11-20 09:00